Welcome to our dedicated page for Trinity Biotech Plc SEC filings (Ticker: TRIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Trinity Biotech鈥檚 FDA submissions, R&D milestones, and global kit sales can be tough鈥攅ach new 10-K or 8-K piles pages of biotech terminology on top of complex accounting notes. If you have ever wondered 鈥淗ow do I decode a Trinity Biotech annual report 10-K simplified?鈥� or searched for 鈥淭rinity Biotech insider trading Form 4 transactions,鈥� you already know the challenge.
Stock Titan solves it. Our AI models break down every Trinity Biotech quarterly earnings report 10-Q filing, highlight segment revenue from infectious-disease kits, and flag changes in diabetes management initiatives. Need real-time alerts? Receive 鈥淭rinity Biotech Form 4 insider transactions real-time鈥� updates the moment executives trade. Our platform also provides concise explanations of Form DEF 14A so you can quickly grasp 鈥淭rinity Biotech proxy statement executive compensation鈥� without digging through compensation tables.
Explore every disclosure in one place: 10-K audits of global manufacturing risks, 8-K material events explained when FDA clearances arrive, and 鈥淭rinity Biotech earnings report filing analysis鈥� that connects R&D spending to pipeline progress. Use our AI-powered summaries鈥攂uilt for understanding Trinity Biotech SEC documents with AI鈥攖o compare quarter-over-quarter HbA1c kit sales, monitor 鈥淭rinity Biotech executive stock transactions Form 4,鈥� and capture red-flags hidden deep in footnotes. Whether you type 鈥淲here can I find Trinity Biotech quarterly earnings report 10-Q filing?鈥� or 鈥淭rinity Biotech SEC filings explained simply,鈥� this page delivers accurate data, plain-language insights, and the confidence to act on them.
Trinity Biotech reported breakthrough clinical trial results for its redesigned continuous glucose monitoring (CGM) sensor, indicating a significant development in its product pipeline. The Form 6-K states the company issued a press release describing those trial results and filed it as Exhibit 99.1. The filing also discloses that on August 7, 2025 the company and certain subsidiaries amended and restated the credit agreement governing their term loan facility with Perceptive Credit Holdings III, L.P. and that a warrant to purchase American Depositary Shares was issued in connection with that agreement. Copies of the press release, the Sixth Amended and Restated Credit Agreement and the warrant certificate are included as Exhibits 99.1, 99.2 and 99.3.
Trinity Biotech plc notified investors via Form 6-K that it issued a press release announcing the launch of an FDA-cleared Preeclampsia Testing Service. The company filed that press release as Exhibit 99.1 to the Form 6-K and stated the report is being incorporated by reference into its Form S-8 registration statements. The filing is signed by Chief Executive Officer John Gillard. The Form contains no financial results, pricing, partner or rollout details, and provides no operational or revenue metrics for the new service.
Trinity Biotech plc (TRIB) filed a Form 6-K to disclose that, on 24 Jul 2025, it released a press announcement for CGM+, an 鈥淎I-native鈥� continuous-glucose-monitoring platform aimed at the estimated $260 bn global AI-wearable market. No financial metrics, guidance, or commercialization timelines were provided in the filing; the full press release is attached as Exhibit 99.1 but not reproduced here. The 6-K is incorporated by reference into the company鈥檚 existing S-8 registration statements.
FAQ
What is the current stock price of Trinity Biotech Plc (TRIB)?
What is the market cap of Trinity Biotech Plc (TRIB)?
